Fig. 7From: RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancerBoxplots showing the differences in a TMB and b TMM, between the different consensus molecular subtypes. * P value < 0.05; ** P value < 0.01, Wilcoxon rank sum test, two-sidedBack to article page